Ally Bridge Group’s Oric Pharmaceuticals ORIC Stock Holding History

Ally Bridge Group’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-485,629	Closed	-$4.93M	–	32
2025 Q2	$4.93M	Buy	+485,629	New	+$3.26M	4.1%	7
2021 Q2	–	Sell	-413,061	Closed	-$10.1M	–	36
2021 Q1	$10.1M	Hold	413,061	–	–	1.94%	16
2020 Q4	$14M	Buy	+413,061	New	+$11.9M	2.4%	13

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Ally Bridge Group's ORIC Position: Q3 2025 in Review

Ally Bridge Group sold out of Oric Pharmaceuticals (ORIC) in Q3 2025, closing a stake of 485,629 shares — an estimated $4.93M sold.

Ally Bridge Group first reported a position in ORIC in Q4 2020 and held it in 3 quarters. The position peaked at $14M in Q4 2020. 152 funds tracked by Wall St. Rank hold ORIC as of Q3 2025.

Ally Bridge Group reported no remaining Oric Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Ally Bridge Group sold 485,629 Oric Pharmaceuticals shares in Q3 2025, an estimated $4.93M.
Ally Bridge Group first reported a position in Oric Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Ally Bridge Group's Oric Pharmaceuticals position peaked at $14M in Q4 2020.
152 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2025.

Based on Ally Bridge Group's 13F filing for Q3 2025, filed 14 Nov 2025.